SERCA2a gene therapy can improve symptomatic heart failure in δ-sarcoglycan-deficient animals.
Ontology highlight
ABSTRACT: The loss of dystrophin or its associated proteins results in the development of muscle wasting frequently associated with cardiomyopathy. Contractile cardiac tissue is injured and replaced by fibrous tissue or fatty infiltrates, leading to a progressive decrease of the contractile force and finally to end-stage heart failure. At the time symptoms appear, restoration of a functional allele of the causative gene might not be sufficient to prevent disease progression. Alterations in Ca(2+) transport and intracellular calcium levels have been implicated in many types of pathological processes, especially in heart disease. On the basis of a gene transfer strategy, we analyzed the therapeutic efficacy of primary gene correction in a δ-sarcoglycan (δ-SG)-deficient animal model versus gene transfe
SUBMITTER: Bouyon S
PROVIDER: S-EPMC4137356 | biostudies-literature | 2014 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA